Science (10): Keap1-Nrf2, flavonoid AIs, TAAR1, TRIM24, HDAC4/7, STELLAR, CYP8B1, cMYC RIBOTAC, p38δ, thrombin DCC — hit-finding and SAR heavy. Business (7): Novo-Ascendis split, Sling raise, BioNTech win, SELLAS fail, Sionna cuts, Merck-PostEra M&A, AZ Enhertu reimbursement.
2026-09-17 · ⚗️Aromatase (CYP19A1) / small-molecule SAR, bioisosteric design · chemRxiv
- Aromatase (CYP19A1) catalyzes the final step converting androgens to estrogens, and its activity drives tumor proliferation in estrogen receptor-positive (ER+) breast cancer, making it a long-validated target for hormonal therapy.
- Existing steroidal and nonsteroidal aromatase inhibitors (AIs) are effective as first-line treatments but face limitations from acquired resistance and off-target/tolerability issues, motivating a search for new chemical starting points.
- Researchers applied bioisosteric replacement strategies to a flavonoid-derived scaffold, a plant-derived chemotype structurally distinct from current AI drug classes, to generate a series of novel candidate inhibitors.
- The substitutions were assessed computationally for how they might alter predicted binding within the CYP19A1 active site, alongside their effects on physicochemical and ADME-relevant properties.
- The overall goal is a lead series that suppresses estradiol biosynthesis while addressing some of the structural liabilities associated with existing AI chemotypes.
💡 PointsA flavonoid core is a bold starting point — it's structurally miles from the triazole-based nonsteroidal AIs (letrozole, anastrozole) and steroidal exemestane, but that novelty cuts both ways. First question: what's actually coordinating the heme iron? Nonsteroidal AIs work because that triazole/imidazole nitrogen chelates Fe3+ — if the bioisosteric swaps didn't install an equivalent, the "improved binding" predictions may be modeling the wrong interaction entirely. Second, flavonoids are notorious for glucuronidation, poor solubility, and promiscuous CYP inhibition (isoform selectivity is the whole AI liability story, not just CYP19A1 potency) — bioisosteric replacement can just relocate those ADME problems rather than fix them. And this is docking/property prediction only; no IC50s, no CYP19A1/CYP3A4 selectivity ratios, no cell data. Promising scaffold idea, but until there's a measured Ki, I'm filing this under "watch, don't chase."
Bioisosteric Design of Novel Flavonoid-Derived Aromatase Inhibitors to Reduce Estradiol Biosynthesis in ER+ Breast Cancer ↗
2026-09-16 · ⚗️cMYC mRNA / RIBOTAC (RNA-targeting degrader modality) · ChemMedChem (Wiley)ChemMedChem 2026, 21 (18)
- RIBOTACs (ribonuclease-targeting chimeras) are heterobifunctional small molecules that recruit an endogenous ribonuclease to degrade a chosen RNA, rather than inhibiting a protein directly.
- This study applies the approach to cMYC mRNA; cMYC is an oncogenic transcription factor long considered "undruggable" because no direct small-molecule inhibitors have reached clinical use.
- Researchers systematically varied the length and rigidity of the linker connecting the RNA-binding ligand to the ribonuclease-recruiting moiety.
- Linker geometry proved to be a key determinant of how efficiently the RIBOTAC promotes cMYC mRNA degradation.
- Optimized linkers translated into improved downstream modulation of cMYC protein levels in cell-based assays.
- The findings support linker engineering as a general design lever for RIBOTAC-based RNA-targeted therapeutics.
💡 PointscMYC is the target every med chemist has scars from — decades of "undruggable" transcription-factor programs that went nowhere, so any credible new handle gets attention. What's genuinely useful here isn't the RIBOTAC concept itself but the linker SAR: length and rigidity dominating degradation efficiency is exactly the PROTAC linkerology lesson replaying in RNA-target space, and it's reassuring that the same design intuition transfers. That said, don't lose sight of the tractability problem — these are still bifunctional, comfortably-beyond-Ro5 molecules with the synthetic and PK baggage PROTACs never fully shook off. And the data are cell-based potency, not in vivo proof of concept; going from "degrades cMYC mRNA in a dish" to "a dosable, selective drug" is still the hard part nobody's solved for this target.
Linker Optimization of cMYC RIBOTAC for Efficient cMYC Modulation ↗
2026-09-16 · ⚗️CYP8B1 / small-molecule hit-to-lead, DMPK-guided optimization · ACS Medicinal Chemistry Letters (ACS)
- CYP8B1 is a liver enzyme in the bile-acid synthesis pathway now being explored as a drug target for metabolic disorders such as nonalcoholic fatty liver disease and type 2 diabetes.
- The project started from compound 1, a CYP8B1 inhibitor identified by high-throughput screening, which broke down too quickly to be tested in live animals.
- Chemists used structure-based design and metabolite identification to learn how the molecule degraded, then ran DMPK-guided analog synthesis to explore structure-activity relationships.
- That work produced compound 9, a quinoline analog with markedly improved metabolic stability.
- In mice, compound 9 showed robust in vivo CYP8B1 inhibition, providing a validated lead for further optimization.
💡 PointsThis is textbook DMPK-guided lead optimization done right: compound 1 degrades too fast for in vivo work, so instead of abandoning it, they identify the metabolite, figure out exactly where the molecule is falling apart, and redesign around that liability. That's the disciplined way to do hit-to-lead, and it's refreshing to see it laid out explicitly rather than glossed over. Landing on a quinoline is a plus for tractability — cheap chemistry, well-understood SAR space, easy to riff on for follow-up analogs. CYP8B1/bile-acid signaling is also a nice change of scenery from the overworked FXR and GLP-1 real estate in NAFLD/T2D. My one nagging question: going from compound 1 to a stable, in vivo-active compound 9 reads suspiciously clean for a single campaign — what substituent or ring modification actually killed the metabolic soft spot? That's the detail I'd want in the SAR table before believing this fully.
Structure-Based Drug Design of Quinoline CYP8B1 Inhibitors for the Potential Treatment of Metabolic Disease ↗
2026-09-16 · ⚗️HDAC4 / HDAC7 (Class IIa histone deacetylases) / small-molecule SAR, isoform-selective inhibitor design · ACS Medicinal Chemistry Letters (ACS)
- HDAC4 and HDAC7 are class IIa histone deacetylases with limited tissue expression, making them attractive, more selective epigenetic drug targets than broadly expressed HDAC family members.
- Both enzymes help drive the transcriptional program behind Th17 cell differentiation, a pathway linked to inflammatory bowel disease and other Th17-associated inflammatory conditions.
- Chemists reworked the metal-binding and hydrophobic contact regions of TMP269, a known class IIa scaffold, to build a new series of HDAC4/7-directed analogs.
- Reporter-gene, binding, and docking studies uncovered distinct structural features that separately steer potency toward HDAC4 versus HDAC7.
- The work delivered isoform-selective, potent compounds usable as chemical probes to separately study HDAC4 and HDAC7 function, and as starting points for Th17-targeted therapeutics.
💡 PointsClass IIa HDACs are the pseudo-catalytic oddballs of the family — barely any intrinsic deacetylase activity, so their biology runs largely through protein contacts rather than a clean catalytic pocket, which is why generic HDAC pharmacophores rarely discriminate them well. Building off TMP269 instead of starting de novo is the pragmatic call: it's a validated class IIa binder, so tuning the metal-binding warhead plus the adjacent hydrophobic contacts is a much more tractable SAR exercise than blind discovery. Pulling HDAC4 vs HDAC7 selectivity out of that is the real win — these two are highly homologous, and clean separation is notoriously hard. Most clinical HDAC drugs are pan- or Class I-selective, so isoform-pure IIa probes are genuinely useful tool compounds for picking apart Th17 biology, well before anyone's thinking about a lead.
Structure-Guided Development of Selective HDAC4 and HDAC7 Inhibitors That Modulate Th17 Cell Transcription ↗
2026-09-15 · ⚗️p38δ (p38 delta MAP kinase) / small-molecule inhibitor, induced-fit pocket remodeling for selectivity · Angewandte Chemie International Edition (Wiley)
- Researchers led by Seidler and colleagues designed a small-molecule inhibitor of p38δ (p38 delta), a MAP kinase linked to cancer, and reported its binding mechanism in Angewandte Chemie International Edition.
- Structural analysis showed the inhibitor initially collided with a flexible loop lining the kinase's ATP-binding pocket, a clash that would normally be expected to weaken or block binding.
- Instead of being excluded, the inhibitor caused that loop to change conformation and fold around the molecule, producing an unusually tight, self-encapsulating fit within the remodeled pocket.
- The authors present this induced-fit, pocket-remodeling behavior as a previously undescribed route to kinase selectivity, distinct from conventional structure-based design, which treats the binding pocket as a fixed template the inhibitor must be shaped to match.
- The finding suggests that deliberately exploiting pocket flexibility, rather than avoiding steric clashes, could become a strategy for engineering selectivity in future kinase-targeted drug design.
💡 PointsThe steric clash was the feature, not the bug — that's the part that makes me sit up. We're trained to treat the ATP pocket as a fixed template and design ligands to fit it; here the loop folded around the inhibitor and the "bad" collision became the selectivity handle. That inverts the whole lock-and-key mental model.
Selectivity-wise, this is a genuinely new lever. Everyone's chasing hinge tweaks, DFG-out, or allosteric pockets — induced self-encapsulation is a different axis entirely, and worth stealing for other kinase programs.
My skepticism: is this designable, or did they get lucky in one series and rationalize it after the crystal structure came back? Rational pocket-remodeling on demand would be huge; a one-off induced-fit anecdote is just a nice paper.
Also worth noting: p38δ is far less drugged than p38α, so any new selectivity trick here has real headroom.
Thinking Outside the Binding Site: A Self‐Encapsulating Kinase Inhibitor Remodels Its Pocket to Achieve Selectivity ↗
2026-09-14 · ⚗️Thrombin / hit-finding via dynamic combinatorial chemistry (DCC), trivalent ligand design · Angewandte Chemie International Edition (Wiley)Angew. Chem. Int. Ed. 2026, 65 (38)
- Researchers applied dynamic combinatorial chemistry (DCC), a hit-finding method in which reversible chemical building blocks assemble and reassemble under target guidance, letting the biological target itself select its best-binding partners.
- A new platform uses short peptide nucleic acid (PNA) tags to template three-fragment combinations, generating a library of 125,000 possible trivalent assemblies screened against thrombin.
- Candidate complexes are isolated by size-exclusion filtration and identified by MALDI mass spectrometry, compressing an entire selection-and-readout cycle to under an hour.
- Thrombin favored combinations engaging its active site and both flanking exosites at once, and this trivalent binding mode underlies the exceptionally tight affinity.
- The winning assembly is a fully reversible inhibitor with sub-picomolar affinity, achieving near-stoichiometric inhibition of thrombin activity.
💡 PointsDCC keeps getting overshadowed by DEL and FBDD, but this is the kind of result that should change that — a sub-hour select-and-read cycle via PNA templating plus MALDI readout tackles the real bottleneck that's always killed DCC in practice: slow kinetics and painful analytics. What actually earns the affinity isn't luck, though — it's rational exploitation of thrombin's well-mapped exosite architecture, deliberately building a trivalent ligand that bridges the active site and both exosites simultaneously. That's textbook multivalency applied with real target knowledge. My immediate skepticism: a PNA-templated trivalent assembly hitting sub-picomolar affinity is almost certainly a big, charged, un-drug-like molecule — I'd want MW, PK, and oral bioavailability numbers before getting excited about anything beyond a tool compound or long-acting parenteral candidate. Still, as a proof of concept for DCC against other exosite-rich or multi-pocket targets, this is a template worth stealing.
Discovery of a Reversible Sub‐Picomolar Thrombin Inhibitor Using DCC ↗
2026-09-14 · ⚗️TRIM24 bromodomain (epigenetic reader) / chemical-biology target identification via genetically encoded photocrosslinking probes (AzF, BzF) · bioRxiv
- TRIM24 is a dual-module epigenetic "reader" whose bromodomain binds acetylated histones and is an established cancer drug-discovery target, though its nonhistone binding partners have been poorly defined.
- Researchers installed genetically encoded photocrosslinkers, AzF and BzF, at residue L922 within the bromodomain's acetyllysine pocket, preserving histone binding while enabling UV-triggered covalent capture of interacting proteins.
- Quantitative proteomics identified the nonhistone proteins NPM1 (AzF-enriched) and CDK9 (BzF-enriched), plus candidates MAP4, RAN, and SND1.
- ChIP-seq showed TRIM24, CDK9, and NPM1 co-localize near transcription start sites of cancer-associated genes; KEGG analysis tied the hits to several signaling pathways.
- The approach shows photocrosslinking can extend reader-domain interactome mapping beyond histones, yielding new candidate leads for chemical-probe and target-discovery work on TRIM24.
💡 Points"Selective bromodomain inhibitor" just got a harder definition. NPM1 and CDK9 turned up riding along at L922 — the acetyllysine pocket where any TRIM24 bromodomain probe or degrader warhead would sit — so selectivity now has to mean selective against displacing these too, not just against other BRD family members. Most bromodomain campaigns are still built structure-first off that pocket alone, chasing histone-mimetic potency; this says the pocket's biology extends past histones, so cellular phenotype from a TRIM24 chemical probe could be confounded by NPM1/CDK9 disruption rather than histone reading per se. No compound here, just a crosslinker — useful, but MAP4, RAN and SND1 are "candidates" in a proteomics list, not validated partners; I'd want co-IP/FP confirmation and dose-response competition before building any SAR narrative around them.
Mapping the Nonhistone Interactome of the TRIM24 Bromodomain Using Genetically Encoded Complementary Photocrosslinkers ↗
2026-09-17 · 💻Keap1-Nrf2 (protein-protein interaction) / virtual screening methodology · chemRxiv
- A new benchmarking study examines a virtual-screening pipeline that chains structure-based co-folding models with learned-affinity scoring, an increasingly common setup for computational hit-finding.
- The cascade was applied to the Keap1-Nrf2 protein-protein interaction, a notoriously hard-to-drug target due to its flat, polar interface.
- Instead of trusting only the final ranked output, the authors assessed each stage separately against experimentally meaningful signal.
- They identify specific points where a stage's score diverges from that signal, a failure mode that can mislead downstream compound prioritization.
- The paper proposes per-stage control checks practitioners can run before relying on a cascade's final hit list, framing the work as a methodology and reliability study rather than a report of a new inhibitor.
💡 PointsKeap1-Nrf2 is exactly the flat, polar PPI where a co-folding model will happily spit out a confident-looking pose and the affinity scorer will rank it #1 for the wrong reasons — so a paper that pries the cascade apart stage-by-stage is more useful to me than another "we found a hit" claim.
What I actually want out of this: a checklist to run on my own vendor or in-house pipeline before I let its top 20 dictate what goes on the synthesis queue. If the co-folding confidence and the affinity score are quietly diverging, that's exactly the failure mode that burns weeks on compounds that never had real signal behind them.
No new chemical matter here, no binding mode to chase — just a reminder that for a target this treacherous, the ranked list is not the QC step. Filed under "read before ordering," not "read for the inhibitor."
Per-Stage Controls and Failure Modes in a Co-Folding Virtual Screening Cascade for the Keap1–Nrf2 Interaction ↗
2026-09-17 · 💻TAAR1 (GPCR) / structure-based virtual screening, hit-to-lead · Nature Communications (Nature)
- TAAR1 is a G protein-coupled receptor pursued as a non-dopaminergic drug target for schizophrenia and antipsychotic therapy.
- A structure-based virtual screen docked about 65 million candidate molecules against an active-state model of TAAR1.
- Of 55 top-ranked hits tested experimentally, 14 showed genuine TAAR1 agonist activity, ranging from mid-nanomolar to micromolar potency.
- Hit optimization then yielded agonists with nanomolar potency, and cryo-EM structures confirmed the binding poses the docking had predicted.
- Three optimized agonists showed high brain exposure and potency described as exceeding that of ulotaront, a clinical-stage TAAR1 antipsychotic candidate.
- In mice, all three normalized amphetamine-induced disruption of pre-pulse inhibition, a schizophrenia-relevant behavioral measure, without causing catalepsy, a common antipsychotic side effect.
💡 PointsA 25% experimental hit rate (14/55) out of 65 million docked molecules is the number that jumps out — that's an unusually clean confirmation rate for an active-state GPCR model, and it's real validation for structure-based virtual screening on TAAR1, not just a docking-score exercise. Better still, cryo-EM backs up the predicted binding poses, so the model isn't just getting lucky on affinity. The pharmacology is the real prize: brain-penetrant, potency beating ulotaront, and no catalepsy in the PPI assay — that's the non-dopaminergic promise actually paying off, not just a slogan. Ulotaront is now the bar every TAAR1 agonist has to clear, and these three cleared it. Worth watching whether the SAR generalizes beyond these three chemotypes.
Structure based discovery of antipsychotic-like TAAR1 agonists ↗
2026-09-16 · 💻Fragment-based docking / computational hit-finding methodology for peptide and biopolymer ligands · Journal of Chemical Information and Modeling (ACS)
- Researchers built STELLAR, a new docking workflow aimed at a persistent problem: current tools poorly handle long, highly flexible biopolymer ligands, including peptides exceeding roughly ten subunits, because of their vast conformational freedom.
- STELLAR splits such ligands into smaller fragments, docks each one separately, then reassembles them into a full-length, physically realistic pose, using established software including GNINA, RDKit, and GROMACS for refinement.
- Tested against known peptide-protein complexes from the Propedia database and the Protein Data Bank, the workflow reproduced experimentally observed binding poses with high accuracy.
- Compared with other state-of-the-art docking tools, it runs mainly on CPUs, scales linearly with ligand length, executes faster, and includes a ranking metric suited to high-throughput screening of long-chain polymer-protein interactions.
💡 PointsTen residues is roughly where my patience with standard docking runs out — past that, chains have so much conformational freedom that I end up either restraining everything by hand or giving up on the exercise. Fragment-then-reassemble is a sensible workaround, and leaning on GNINA/RDKit/GROMACS instead of a black-box neural net means I can actually inspect intermediate poses. CPU-only, linear scaling is the detail that matters most day-to-day: no GPU queue, no cloud bill, just run it on the workstation overnight for a stapled-peptide library. Most ML docking tools give me a score with no real confidence handle for ranking; a purpose-built ranking metric for long-chain ligands is genuinely missing elsewhere. That said, Propedia/PDB benchmarks are known complexes — reproducing a crystal pose isn't the same as correctly ranking novel binders against a target with no solved structure. Worth a pilot run, not a blind swap-in.
STELLAR: A Fragment-Based Docking Workflow for Highly Flexible Long-Chain Biopolymers ↗
2026-09-17 · 🏢Regulatory/reimbursement — market access policy · STAT News · AstraZeneca / Daiichi Sankyo
- Enhertu (trastuzumab deruxtecan), an AstraZeneca/Daiichi Sankyo HER2-targeting antibody-drug conjugate, will now be reimbursed by NHS England for HER2-low metastatic breast cancer.
- The move reverses NICE's July 2024 rejection of the drug for this indication, ending a years-long access dispute.
- It follows a new NICE agreement made possible by a broader U.S.-U.K. drug pricing deal (announced December 2025), which raised NICE's cost-effectiveness thresholds from about £20,000-£30,000 to £25,000-£35,000 per quality-adjusted life year.
- A new quality-of-life assessment methodology, published August 27, 2026, also supported the reassessment.
- About 1,000 women a year in England with HER2-low metastatic breast cancer are expected to now qualify, with studies reporting an average survival gain of roughly six months.
💡 PointsThe science and data here are unchanged from NICE's 2024 rejection — this is a payer-economics win, not a clinical one, and it's easy to conflate the two. What actually moved was NICE's cost-effectiveness ceiling, from roughly £20-30K to £25-35K per QALY, engineered by the broader US-UK pricing deal, not new trial results. That's the real story: the first tangible commercial outcome traceable to that trade agreement, and it hands every company with a NICE-rejected asset a concrete playbook for reopening the case. Commercially, ~1,000 patients/year in England is a rounding error for AZ/Daiichi's global Enhertu franchise — the payoff is precedent, not revenue. Watch for ripple effects: rival ADCs and other HER2-low contenders now face a materially easier cost-effectiveness bar, reshaping competitive dynamics in an increasingly crowded ADC pipeline.
England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing deal ↗
2026-09-17 · 🏢Trial result (negative/failure) · STAT News · SELLAS Life Sciences
- SELLAS Life Sciences' galinpepimut-S (GPS) is a WT1-targeting peptide immunotherapy.
- The pivotal Phase 3 REGAL trial enrolled more than 100 acute myeloid leukemia (AML) patients in second remission, randomized to GPS versus physician's choice of treatment, with the primary goal of demonstrating improved overall survival.
- The trial is event-driven, requiring 80 patient deaths before a final analysis can be conducted; reporting indicates the event count is nearing that threshold.
- The trial's conclusion has been delayed by nearly a year.
- Per STAT News reporting by biotech columnist Adam Feuerstein, the long-delayed REGAL trial is expected to end in failure, with GPS not expected to show a survival benefit over standard of care.
- A negative outcome would represent a significant setback for SELLAS's lead clinical program.
💡 PointsNearly a year late to hit its death-count threshold — that delay is the real signal in this story, not a footnote. Event-driven trials that take longer than planned to accrue events are rarely good news: if the treatment arm were meaningfully extending survival, events would accrue slower and the delay would read as encouraging, not ominous. That REGAL is reportedly headed for failure fits a pattern, not an anomaly. This is SELLAS's lead asset, so a negative confirmatory readout isn't a pipeline setback — it's closer to an existential one for a small-cap with limited runway and few near-term catalysts to fall back on. It also adds another data point to WT1-targeting peptide vaccines' long, mostly disappointing history in AML, a mechanism that has struggled to translate immunogenicity into survival benefit across multiple sponsors. Expect a sharp reassessment of remaining pipeline value, cash runway, and financing options once/if this is confirmed.
A Sellas immunotherapy study, long delayed, will end in failure ↗
2026-09-16 · 🏢Financing / pipeline progress · Fierce Biotech · Sling Therapeutics
- Sling Therapeutics closed a $123 million Series C financing round led by Forbion, with participation from existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management.
- Proceeds will fund a Phase 3 trial of linsitinib, an oral small-molecule inhibitor of IGF-1R (insulin-like growth factor 1 receptor), for thyroid eye disease (TED).
- Linsitinib was originally developed by Astellas as a cancer treatment; Sling licensed the compound in 2022 and repositioned it for TED.
- The drug is being developed as an oral alternative to Amgen's infused antibody Tepezza (teprotumumab), the current standard treatment for TED.
- The Phase 3 trial has begun dosing patients, targeting roughly 120 participants, and is evaluating linsitinib's ability to reduce proptosis (eyeball bulging) over a 24-week period.
💡 PointsTepezza turned thyroid eye disease into a blockbuster franchise despite being an IV-infused biologic — an oral IGF-1R inhibitor now running its own Phase 3 is the first mechanism-matched threat with real clinical data behind it, and Amgen should take notice. The deal's backstory is arguably the sharper story: an Astellas oncology asset shelved, licensed out in 2022, and repositioned for ophthalmology now sits in pivotal testing — the underappreciated-asset playbook every BD team wants to replicate. A $123M Series C landing at Phase 3, not an earlier round, with Forbion leading and new crossover-style investor Sectoral joining incumbent TPG, reads as genuine conviction, not speculative money chasing a hot indication. TED is a small, rare-disease market, but Tepezza proved payers and patients will pay for relief — an oral, self-administered option could expand that funnel further if the proptosis data holds up at 24 weeks.
Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial ↗
2026-09-15 · 🏢Partnership termination · Fierce Biotech · Novo Nordisk / Ascendis Pharma
- Novo Nordisk has terminated its partnership with Ascendis Pharma to co-develop a once-monthly GLP-1 receptor agonist for obesity and diabetes.
- The collaboration was signed in November 2024 and licensed Ascendis's TransCon sustained-release drug delivery platform to Novo for its lead once-monthly program.
- Under the original agreement, Ascendis was eligible for up to $285 million in combined upfront, development, and regulatory milestone payments, plus potential tiered royalties.
- The goal was a monthly-dosed treatment intended to compete with existing daily and weekly GLP-1 drugs on the market.
- Novo ended the collaboration less than two years after it began, with no monthly GLP-1 product having resulted from the partnership.
💡 PointsA sub-$300M deal dying in under two years, with no candidate ever reaching the clinic, is a cheap off-ramp — Novo exits with minimal sunk cost, unlike a late-stage termination. That's the tell: this reads less as a verdict on Ascendis's TransCon chemistry and more as Novo reprioritizing internally under intense competitive pressure from Lilly's tirzepatide franchise and oral orforglipron. Killing a monthly-dosing bet also raises a sharper question: is weekly GLP-1 dosing already "good enough," with the real prize shifting to oral convenience instead? For Ascendis, the financial hit is small but the strategic one isn't — losing a big-pharma validation partner for TransCon undermines the platform story just as investors want proof the delivery tech, not just the molecule, is what pharma will pay up for.
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis ↗
2026-09-15 · 🏢Discontinuation / restructuring (following trial failure) · Fierce Biotech · Sionna Therapeutics
- Sionna Therapeutics is cutting approximately 46% of its workforce as part of a broader strategic restructuring.
- The move follows the failure of a clinical trial testing SION-719, an NBD1 stabilizer, as an add-on cystic fibrosis (CF) therapy.
- SION-719 was tested alongside Vertex Pharmaceuticals' Trikafta in CF patients homozygous for the F508del mutation.
- The trial did not produce a statistically significant reduction in sweat chloride, a standard biomarker used to gauge CFTR modulator efficacy in CF.
- Sionna's program had aimed to build on and improve outcomes beyond the market-leading Trikafta regimen.
- The layoffs and pipeline reprioritization mark a strategic shift for the company following this clinical setback.
💡 PointsTrikafta's add-on moat just claimed another name. SION-719 joins a growing list of CF programs that have failed to clear the sweat-chloride bar once layered on top of triple-combo therapy — a pattern that says less about any one company's execution and more about how close to a ceiling Trikafta already sits. That's the more interesting read for the mechanism itself: NBD1 stabilization is scientifically rational (Vertex runs its own NBD1 programs internally), yet delivering a clean, statistically significant delta on top of an already-near-maximal correction is proving brutally hard across the class, not just for Sionna. A 46% headcount cut is not routine trimming — it's a company betting its remaining cash runway on a sharply narrowed, likely earlier-stage pipeline rather than continuing broad-front development. Net effect for the competitive landscape: one fewer credible Trikafta challenger, which further entrenches Vertex's CF monopoly and eases pressure on both its pricing power and its own pipeline urgency.
Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail ↗
2026-09-14 · 🏢Trial result (positive with tolerability caveat) · Fierce Biotech · BioNTech / OncoC4
- Gotistobart (BNT316/ONC-392), a CTLA-4-targeting monoclonal antibody from BioNTech and partner OncoC4, is designed to selectively deplete regulatory T cells within the tumor microenvironment.
- Updated stage 1 data from the global Phase 3 PRESERVE-003 trial were presented at the IASLC 2026 World Conference on Lung Cancer.
- The trial enrolled previously treated metastatic squamous non-small cell lung cancer (NSCLC) patients whose disease had progressed on prior immunotherapy and chemotherapy.
- Gotistobart nearly doubled median overall survival to 18.5 months versus 10.0 months for docetaxel chemotherapy, a statistically significant and clinically meaningful benefit (hazard ratio 0.56).
- Fierce Biotech's coverage noted the drug poses a tolerability challenge alongside this survival benefit.
- The pivotal stage 2 portion of PRESERVE-003 is ongoing at more than 160 sites worldwide.
💡 PointsCTLA-4 carries baggage — ipilimumab's toxicity effectively exiled the class to combo-backup duty, so gotistobart's whole pitch is "selective Treg depletion solves what ipi couldn't." A tolerability flag showing up in the very same headline as the efficacy win is the tension to watch, not a footnote. That said, nearly doubling median OS (18.5 vs 10.0 months, HR 0.56) in post-IO/chemo squamous NSCLC is a genuinely hard bar to clear — this is BioNTech's most credible non-mRNA oncology proof point yet, a real diversification lever beyond the vaccine franchise. It's also OncoC4's asset first: a clean stage 2 readout would meaningfully strengthen OncoC4's hand on deal economics with BioNTech, not just validate the science. Market-wise, the OS number is a legitimate re-rating catalyst, but "tolerability concerns" in the same breath keeps enthusiasm capped until discontinuation and grade 3+ rates surface from the pivotal cohort.
BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial but poses tolerability challenge ↗
2026-09-11 · 🏢M&A / licensing · C&EN (Chemical & Engineering News) · Merck KGaA (EMD Serono) / PostEra
- Merck KGaA, through its EMD Serono fertility business, has agreed to acquire two oral small-molecule fertility drug candidate programs from PostEra for an undisclosed sum described as "mid-double-digit millions."
- Both programs are orally administered small molecules, contrasting with the injectable biologics that currently dominate fertility treatment.
- One program comprises FSHR (Follicle-Stimulating Hormone Receptor) agonists intended for ovarian stimulation during IVF.
- The other comprises LHCGR (Luteinizing Hormone/Choriogonadotropin Receptor) agonists aimed at male infertility and triggering ovulation during IVF.
- PostEra, an AI-driven drug-design startup named one of C&EN's "10 Start-Ups to Watch" in 2025, developed both candidate series using its computational platform.
💡 PointsA bolt-on, not a market entry: EMD Serono is already a top-three fertility player commercially, so this reinforces an existing franchise rather than opening a new front — low-risk portfolio strategy. The real story is oral-vs-injectable: IVF stimulation has run almost entirely on injectable biologics for decades, and a credible oral FSHR/LHCGR agonist would be a genuine convenience disruption, expanding the addressable market to patients who avoid treatment due to injection burden. On price, "mid-double-digit millions" for two early/preclinical programs is a small, platform-validation-scale bet, not a transformative deal — size expectations accordingly. And for PostEra, getting bought for its output rather than its platform is a telling data point in the AI-drug-discovery debate: near-term value may sit in the assets, not the software.
Merck KGaA buys PostEra's oral fertility molecules ↗